Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PTBP1 | P26599 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923610 | 0.87 | ATM (0.64) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL536297 | 0.87 | TSHR (0.74) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL3294932 | 0.86 | POLB (0.57) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL14583 | 0.84 | POLB (0.56) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL286034 | 0.84 | ALDH1A1 (0.61) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL13674 | 0.84 | CACNA1F (0.62) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL2776267 | 0.84 | TSHR (0.70) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL286360 | 0.84 | GPBAR1 (0.62) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL899450 | 0.84 | POLB (0.56) | MAPK1POLBALOX15TSHRL3MBTL1 | |
| SCHEMBL2780502 | 0.84 | GPBAR1 (0.58) | MAPK1POLBALOX15TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231651-B1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-11-21 | — | — | EP | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2767536-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-7943619-B2 | Isoxazolo-pyridazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2231651-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009071477-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| US-7053219-B2 | Isoxazolopyridone derivatives and their use | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20040176407-A1 | Novel isoxazolopyridone derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1408042-A1 | NOVEL ISOXAZOLOPYRIDONE DERIVATIVES AND USE THEREOF | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | MAPK1 2735/4885POLB 3831/4885ALOX15 2796/4885 |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | MAPK1 3025/4885POLB 2720/4885ALOX15 689/4885 |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | MAPK1 2784/4885POLB 3764/4885ALOX15 2541/4885 |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | MAPK1 2784/4885POLB 3764/4885ALOX15 2541/4885 |
| US-20040176407-A1 | Novel isoxazolopyridone derivatives and their use | GRIN2A, GRM2, GRM1 | MAPK1 1978/4885POLB 3731/4885ALOX15 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.